|
|
|
|
|
|
Companies > Preclinical
|
|
|
Visum Therapeutics is developing a small molecule therapeutic to treat Stargardt's disease, a degenerative condition that leads to blindness and is the most common form of inherited juvenile macular degeneration. Much of the pathology of Stargardt’s disease is shared with the more common Age-related Macular Degeneration (AMD).
|
|
|
|
|